{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:09:04Z","timestamp":1776938944186,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the USA. Our institution has treated over 2000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New York.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020, and April 30, 2020. We report epidemiological, clinical, and laboratory characteristics including the persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67\u2009years; 52% of patients were male and 63% were non-White. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (24%), and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (&gt; 70\u2009years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-White race, and mortality. Ninety-six percent (22\/23) of patients developed antibodies to SARS-CoV-2 at a median of 32\u2009days after initial diagnosis. The median time to PCR negativity was 43 (range 19\u201368) days from initial positive PCR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia was associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to the identification of vulnerable MM patients who need early intervention to improve outcomes in future outbreaks of COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-020-00934-x","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:38:34Z","timestamp":1594719514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward"],"prefix":"10.1186","volume":"13","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane Marie","family":"Del Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-9690","authenticated-orcid":false,"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"934_CR1","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020."},{"key":"934_CR2","unstructured":"Robilotti EV, Babady NE, Mead PA, et al. Determinants of severity in cancer patients with COVID-19 illness. medRxiv. 2020; 2020.05.04.20086322."},{"key":"934_CR3","doi-asserted-by":"crossref","unstructured":"Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020.","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335\u20137.","journal-title":"Lancet Oncol"},{"key":"934_CR5","doi-asserted-by":"crossref","unstructured":"Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020.","DOI":"10.1101\/2020.02.22.20025320"},{"key":"934_CR6","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020.","DOI":"10.1016\/j.annonc.2020.03.296"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-319-40320-5_12","volume":"169","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Borrello I. Role of the immune response in disease progression and therapy in multiple myeloma. Cancer Treat Res. 2016;169:207\u201325.","journal-title":"Cancer Treat Res"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","volume":"22","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, Anderson KC. Immune therapies in multiple myeloma. Clin Cancer Res. 2016;22:5453\u201360.","journal-title":"Clin Cancer Res"},{"key":"934_CR10","unstructured":"Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med."},{"key":"934_CR11","doi-asserted-by":"crossref","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"934_CR12","doi-asserted-by":"crossref","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020.","DOI":"10.1038\/s41577-020-0331-4"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","volume":"11","author":"D Liu","year":"2018","unstructured":"Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11:121.","journal-title":"J Hematol Oncol"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"934_CR15","doi-asserted-by":"crossref","unstructured":"Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;105954.","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395:1033\u20134.","journal-title":"Lancet (London, England)"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395:497\u2013506.","journal-title":"Lancet (London, England)"},{"key":"934_CR18","doi-asserted-by":"crossref","unstructured":"Gong J, Dong H, Xia SQ, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. medRxiv. 2020; 2020.02.25.20025643.","DOI":"10.1101\/2020.02.25.20025643"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ejh.12728","volume":"97","author":"R S\u00f8rrig","year":"2016","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol. 2016;97:303\u20139.","journal-title":"Eur J Haematol"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"e0200043","DOI":"10.1371\/journal.pone.0200043","volume":"13","author":"DG Widman","year":"2018","unstructured":"Widman DG, Gornisiewicz S, Shacham S, Tamir S. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals. PLoS One. 2018;13:e0200043.","journal-title":"PLoS One"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.bbrc.2018.07.112","volume":"503","author":"M Wu","year":"2018","unstructured":"Wu M, Gui H, Feng Z, et al. KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis. Biochem Biophys Res Commun. 2018;503:1773\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"934_CR24","doi-asserted-by":"crossref","unstructured":"Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematol. 2020:1\u20137.","DOI":"10.1159\/000507690"},{"key":"934_CR25","volume-title":"Recommendations for the management of myeloma patients during the COVID-19 pandemic","author":"IM Society","year":"2020","unstructured":"Society IM. Recommendations for the management of myeloma patients during the COVID-19 pandemic; 2020."},{"key":"934_CR26","doi-asserted-by":"crossref","unstructured":"Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol. 2020.","DOI":"10.1016\/S2352-3026(20)30124-1"},{"key":"934_CR27","unstructured":"COVID-19: Data. 2020. at https:\/\/www1.nyc.gov\/site\/doh\/covid\/covid-19-data.page.)."},{"key":"934_CR28","unstructured":"Cook G, Ashcroft AJ, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy. Br J Haematol."},{"key":"934_CR29","doi-asserted-by":"crossref","unstructured":"Gross CP, Essien UR, Pasha S, Gross JR, Wang S-Y, Nunez-Smith M. Racial and ethnic disparities in population level COVID-19 mortality. medRxiv. 2020; 2020.05.07.20094250.","DOI":"10.1101\/2020.05.07.20094250"},{"key":"934_CR30","doi-asserted-by":"crossref","unstructured":"Henning-Smith C, Tuttle M, Kozhimannil KB. Unequal distribution of COVID-19 risk among rural residents by race and ethnicity. J Rural Health. 2020.","DOI":"10.1111\/jrh.12463"},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/jgs.14472","volume":"65","author":"G Howard","year":"2017","unstructured":"Howard G, Safford MM, Moy CS, et al. Racial differences in the incidence of cardiovascular risk factors in older Black and White adults. J Am Geriatr Soc. 2017;65:83\u201390.","journal-title":"J Am Geriatr Soc"},{"key":"934_CR32","doi-asserted-by":"crossref","unstructured":"Diane Marie Del Valle M, Seunghee Kim-Schulze PD, Hsin-Hui Huang PD, et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. MEDRXIV. 2020;115758.","DOI":"10.1101\/2020.05.28.20115758"},{"key":"934_CR33","doi-asserted-by":"crossref","unstructured":"Jatiani SS, Aleman A, Madduri D, et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin Lymphoma MyelomaLeukemia. 2020.","DOI":"10.1016\/j.clml.2020.04.020"},{"key":"934_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13:30.","journal-title":"J Hematol Oncol"},{"key":"934_CR35","doi-asserted-by":"crossref","unstructured":"Costa LJ WS, Berm\u00fadez A. First clinical study of the B-cell maturation antigen (BCMA) 2 + 1\u2009T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Abstract #143. American Society of Hematology. Orlando: ASH Annual Meeting Proceedings; 2019.","DOI":"10.1182\/blood-2019-122895"},{"key":"934_CR36","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117:10970\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"934_CR37","doi-asserted-by":"crossref","unstructured":"Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020.","DOI":"10.1016\/j.jaci.2020.05.019"},{"key":"934_CR38","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.4049\/jimmunol.174.12.7977","volume":"174","author":"C-TK Tseng","year":"2005","unstructured":"Tseng C-TK, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174:7977\u201385.","journal-title":"J Immunol"},{"key":"934_CR39","doi-asserted-by":"crossref","unstructured":"Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv. 2020; 2020.05.18.20099960.","DOI":"10.1101\/2020.05.18.20099960"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00934-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:18:56Z","timestamp":1626207536000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00934-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00934-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.04.20122846","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice (IRB: GCO#: 11-1433).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.C.: Advisory board and consulting fees from Amgen, Antegene, Celgene, Janssen, Karyopharm, Millennium\/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi; research funding from Amgen, Celgene, Janssen, Millennium\/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J.: Advisory board and consulting fees from Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals and Merck. H. J. C: Employed by the Multiple Myeloma Research Foundation, advisory board and consulting fees from Genetech, Celgene, Bristol Myers Squibb, GlaxoSmithKline and received research funding from Takeda, Celgene, and Genetech. D. M.: Advisory board and consulting fees from Janssen, Celgene, Bristol Myers Squibb, Takeda, Legend, GlaxoSmithKline, Kinevant, and Foundation Medicine. B.W.: Consulting fees from Sanofi Genzyme. J. R.: Speaking fees from Celgene and Janssen, advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. P.: Consulting fees from Foundation Medicine, research funding from Celgene and Karyopharm, supported by 1R01CA244899-01A1. All other authors declare no potential conflict of interest<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}